Know Cancer

forgot password

Phase 1
18 Years
Open (Enrolling)

Thank you

Trial Information

Inclusion Criteria:

1. Able and willing to give valid written informed consent before undergoing any
study-related activities.

2. Patients with histological documentation of AJCC stage III or IV melanoma of the
skin, mucosa, eye or unknown primary.

3. Unable to undergo resection of all metastatic disease.

4. Negative serology for HBV, HCV, HIV and Syphilis. If positive results for HepB or
Syphilis indicate immunity and are not indicative of active infection, the patient
can enter the study.

5. Adequate venous access that allows to undergo leucapheresis.

6. Having failed first line treatment with DTIC based chemotherapy

7. Full recovery from all prior therapies. A minimum of 4 weeks (6 weeks in case of
prior treatment with nitrosurea or Mitomycin C) should separate the last day of prior
treatment administration and the date of informed consent.

8. WHO performance status of 0, 1 or 2 (see Appendix D).

9. Male and female patients ≥ 18 years of age.

10. Laboratory parameters should be within normal range, except for the following
laboratory parameters, which must be within the ranges specified:see protocol.

11. Viral tests:HIV,HBV and HCV

12. Women of childbearing potential (WOCBP) must be using an adequate method of
contraception to avoid pregnancy throughout the study and for up to 8 weeks after the

13. Patients must be willing to cooperate for the whole period of the study.

Exclusion Criteria:

1. Evidence of immunodeficiency. Autoimmune disease requiring medical treatment

2. Any serious acute or chronic illnesses or other conditions requiring concurrent
medications not allowed during this study.

3. History of malignancy.

4. Inability to undergo PET/CT or MRI examination.

5. Mental impairment that may compromise the ability to give informed consent and comply
with the requirements of the study.

6. Participation in any other clinical trial involving another investigational agent
within 4 weeks prior to enrollment.

7. Subject is pregnant or is currently breast-feeding, anticipates becoming pregnant/
impregnating their partner during the study or within 6 months after study
participation, or subject does not agree to follow acceptable methods of birth
control, such as hormonal contraception, intra-uterine pessary, condoms or
sterilization, to avoid conception during the study and for at least 6 months after
receiving the last dose of study treatment.

8. Current alcohol dependence or drug abuse.

9. Known hypersensitivity to the study treatment.

10. Legal incapacity or limited legal capacity.

11. Presence of any psychological, familial, sociological, or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule.

12. Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family
members who suffer(ed) from such.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

a new tumor evaluation (PET/CT)

Outcome Time Frame:

24 weeks

Safety Issue:


Principal Investigator

Bart Neyns, Professor

Investigator Role:

Principal Investigator

Investigator Affiliation:

UZ Brussel


Belgium: Federal Agency for Medicines and Health Products, FAMHP

Study ID:




Start Date:

December 2009

Completion Date:

September 2014

Related Keywords:

  • Melanoma
  • stage IIIC/IV melanoma
  • Melanoma